It was a nice run, ViroPharma (NAS: VPHM) , but all good things must come to an end.
And what a long run for Vancocin it was.
ViroPharma picked up the antibiotic from Eli Lilly (NYS: LLY) in 2004 for $120 million. The patent ran out decades ago, but the drug is so difficult to make that the Food and Drug Administration hadn't approved any generics.
And it still took three more years for the FDA to approve a generic -- three generics, actually -- from Watson Pharmaceuticals, Akorn (NAS: AKRX) , and Strides Arcolab.
The launch of generic Vancocin will indirectly affect Optimer Pharmaceuticals (NAS: OPTR) and marketing partner Cubist Pharmaceuticals (NAS: CBST) , which sell Dificid to treat the same type of infection. But considering that Dificid's label says it's superior to Vancocin, I doubt the cheaper cost will affect sales much. When a doctor is treating a nasty infection, efficacy will trump cost.
ViroPharma was hoping a label expansion would delay the generic launches for three more years. The company has said it will sue, but I think it's best to assume that won't go anywhere and write off the nearly $300 million in sales. Even ViroPharma seems to think so; it established a supply agreement with Prasco Laboratories to launch an authorized generic to compete with the recently approved generics.
The loss of over half of ViroPharma's revenue will hurt the bottom line, but the company looks more appealing as an investment now than it did in the preceding eight years because it's much easier to value. Before, you had a company where investors knew generics would come eventually, but there was no way to know when. Discounting that uncertainty was difficult.
Now you've got a company with one drug, Cinryze, which treats an orphan indication (hereditary angioedema), contributing a vast majority of the revenue. ViroPharma expects sales of Cinryze in the $310 million to $330 million range, a 23% to 31% increase on last year. At a market cap of $1.5 billion, ViroPharma looks fairly valued with upside if ViroPharma can continue increasing sales of Cinryze.
At the time thisarticle was published Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool has a disclosure policy.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.